Christopher J. Senner - Jan 2, 2025 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ Brendan Hannah, Attorney-in-Fact
Stock symbol
QNCX
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/8/2025, 07:29 PM
Previous filing
Nov 19, 2024
Next filing
Jan 17, 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.